We also find that lumbrokinase treatment inactivates NF-κB signaling and alleviates the binding of p50/p65 at the COX-2 promoter, leading to the down-regulation of COX-2 expression, and eventually sensitized NSCLC cells to chemotherapy. This evidence concerns the gene NFKB1 and non-small cell lung carcinoma.